CUSIP 558868105 · who reports it, how much, and how much it matters to them
48 of the 720 hedge fund managers we track reported shares of Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) on Form 13F for 30 June 2026. Between them they reported USD 4.4bn. The largest position belongs to Baker Bros. Advisors, at USD 1.2bn. The manager with the most riding on it is RTW Investments, where it is 9.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Baker Bros. Advisors2 funds on PPLI.com | USD 1.2bn | 5.8% |
| 2 | RTW Investments2 funds on PPLI.com | USD 1.1bn | 9.1% |
| 3 | Avoro Capital Advisors1 fund on PPLI.com | USD 984m | 8.8% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 272m | 0.0% |
| 5 | Armistice Capital1 fund on PPLI.com | USD 155m | 1.9% |
| 6 | Polar Capital LLP26 funds on PPLI.com | USD 131m | 0.3% |
| 7 | Artisan Partners1 fund on PPLI.com | USD 113m | 0.2% |
| 8 | Rock Springs Capital Management2 funds on PPLI.com | USD 94m | 4.6% |
| 9 | Holocene Advisors2 funds on PPLI.com | USD 82m | 0.2% |
| 10 | POINT72 Asset Management17 funds on PPLI.com | USD 74m | 0.1% |
| 11 | Marshall Wace LLP84 funds on PPLI.com | USD 55m | 0.0% |
| 12 | Millennium Management6 funds on PPLI.com | USD 44m | 0.0% |
| 13 | Alkeon Capital Management19 funds on PPLI.com | USD 43m | 0.1% |
| 14 | Balyasny Asset Management25 funds on PPLI.com | USD 42m | 0.1% |
| 15 | Renaissance Technologies13 funds on PPLI.com | USD 25m | 0.0% |
| 16 | D. E. Shaw & Co.15 funds on PPLI.com | USD 19m | 0.0% |
| 17 | PFM Health Sciences3 funds on PPLI.com | USD 16m | 1.4% |
| 18 | Weiss Asset Management5 funds on PPLI.com | USD 10m | 0.1% |
| 19 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 10m | 0.4% |
| 20 | Sphera Funds Management1 fund on PPLI.com | USD 9.4m | 1.2% |
| 21 | Tudor Investment Corporation10 funds on PPLI.com | USD 6.2m | 0.0% |
| 22 | Jain Global1 fund on PPLI.com | USD 5.9m | 0.0% |
| 23 | Verition Fund Management3 funds on PPLI.com | USD 4m | 0.0% |
| 24 | Brevan Howard Capital Management39 funds on PPLI.com | USD 3.5m | 0.0% |
| 25 | J. Goldman & Co.1 fund on PPLI.com | USD 2.7m | 0.1% |
| 26 | Cinctive Capital Management5 funds on PPLI.com | USD 2.4m | 0.1% |
| 27 | Exoduspoint Capital Management7 funds on PPLI.com | USD 1.8m | 0.0% |
| 28 | Aquatic Capital Management3 funds on PPLI.com | USD 1.7m | 0.1% |
| 29 | HighVista Strategies27 funds on PPLI.com | USD 1.5m | 0.3% |
| 30 | Squarepoint Ops7 funds on PPLI.com | USD 1.3m | 0.0% |
| 31 | LMR Partners2 funds on PPLI.com | USD 1.1m | 0.0% |
| 32 | Hudson Bay Capital Management8 funds on PPLI.com | USD 1.1m | 0.0% |
| 33 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 1,000,000 | 0.0% |
| 34 | Boothbay Fund Management2 funds on PPLI.com | USD 997,000 | 0.0% |
| 35 | Palo Alto Investors6 funds on PPLI.com | USD 960,000 | 0.1% |
| 36 | Freestone Grove Partners1 fund on PPLI.com | USD 833,000 | 0.0% |
| 37 | Cannon Global Investment Management2 funds on PPLI.com | USD 805,000 | 2.3% |
| 38 | Engineers Gate Manager1 fund on PPLI.com | USD 709,000 | 0.0% |
| 39 | Mount Lucas Management2 funds on PPLI.com | USD 605,000 | 0.2% |
| 40 | Diametric Capital2 funds on PPLI.com | USD 515,000 | 0.1% |
| 41 | CIBC Asset Management69 funds on PPLI.com | USD 381,000 | 0.0% |
| 42 | Seelaus Asset Management8 funds on PPLI.com | USD 335,000 | 0.2% |
| 43 | Scientech Research2 funds on PPLI.com | USD 318,000 | 0.3% |
| 44 | Two Sigma Investments35 funds on PPLI.com | USD 304,000 | 0.0% |
| 45 | Graticule Asia Macro Advisors8 funds on PPLI.com | USD 84,838 | 0.0% |
| 46 | Persistent Asset Partners10 funds on PPLI.com | USD 28,995 | 0.0% |
| 47 | Bayforest Capital1 fund on PPLI.com | USD 23,626 | 0.0% |
| 48 | The Quarry1 fund on PPLI.com | USD 2,148 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | RTW Investments | USD 1.1bn | 9.1% |
| 2 | Avoro Capital Advisors | USD 984m | 8.8% |
| 3 | Baker Bros. Advisors | USD 1.2bn | 5.8% |
| 4 | Rock Springs Capital Management | USD 94m | 4.6% |
| 5 | Cannon Global Investment Management | USD 805,000 | 2.3% |
| 6 | Armistice Capital | USD 155m | 1.9% |
| 7 | PFM Health Sciences | USD 16m | 1.4% |
| 8 | Sphera Funds Management | USD 9.4m | 1.2% |
| 9 | Arrowmark Colorado Holdings | USD 10m | 0.4% |
| 10 | HighVista Strategies | USD 1.5m | 0.3% |
Madrigal Pharmaceuticals, Inc. trades under the symbol MDGL on the Nasdaq. Its CUSIP, the code used on Form 13F, is 558868105.
48 of the 720 hedge fund managers PPLI.com tracks reported Madrigal Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Baker Bros. Advisors (USD 1.2bn), RTW Investments (USD 1.1bn), Avoro Capital Advisors (USD 984m), Citadel Advisors (USD 272m) and Armistice Capital (USD 155m).
48 managers in our coverage reported it, and between them they run 574 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
RTW Investments, where the position was 9.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Madrigal Pharmaceuticals, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.